Related references
Note: Only part of the references are listed.Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia
Markus Mueschen
BLOOD (2015)
Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia
Huimin Geng et al.
CANCER CELL (2015)
FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
Barry W. Miller et al.
CLINICAL CANCER RESEARCH (2015)
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
Ute Fischer et al.
NATURE GENETICS (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia
Lieke C. J. van den Berk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
HAEMATOLOGICAL CANCER Idelalisib-targeting PI3Kδ in patients with B-cell malignancies
Jan A. Burger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Idelalisib - A PI3Kδ Inhibitor for B-Cell Cancers
David A. Fruman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
Bhagwan Yadav et al.
SCIENTIFIC REPORTS (2014)
Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
Edward Allan R. Sison et al.
MOLECULAR CANCER RESEARCH (2013)
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Tea Pemovska et al.
CANCER DISCOVERY (2013)
Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter
Maria A. Whitehead et al.
BIOCHEMICAL JOURNAL (2012)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia
Vincent T. Bicocca et al.
CANCER CELL (2012)
A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3
Pablo Cingolani et al.
FLY (2012)
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt et al.
GENOME RESEARCH (2012)
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Hanna L. M. Koskela et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12
Alison M. McCaig et al.
PLOS ONE (2012)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
Identification of fusion genes in breast cancer by paired-end RNA-sequencing
Henrik Edgren et al.
GENOME BIOLOGY (2011)
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia
Thomas Burmeister et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Matthias Niedermeier et al.
BLOOD (2009)
Regulation of p110δ PI 3-Kinase Gene Expression
Klaartje Kok et al.
PLOS ONE (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion
S. A. Mehta et al.
ONCOGENE (2007)
Microenvironmental niches in the bone marrow required for B-cell development
T Nagasawa
NATURE REVIEWS IMMUNOLOGY (2006)
Share Paper
